Karyopharm Therapeutics (KPTI) Price to Book (2013 - 2026)

Karyopharm Therapeutics (KPTI) has reported Price to Book for 14 consecutive years, with 0.86 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 448.97% year-over-year to 0.86; the trailing twelve-month figure through Jun 2026 stood at 0.86 (down 448.97% YoY), and the FY2025 full-year result was 0.27, up 40.1% from the prior year.
• Price to Book retreated to 0.86 in Q2 2026 per KPTI's latest filing, from 0.27 in the prior quarter.
• Across five years, Price to Book topped out at 0.16 in Q1 2025 and bottomed at 16.71 in Q4 2022.
• Historically, Price to Book has averaged 2.92 across 5 years, with a median of 0.86 in 2026.
• The sharpest annual moves came in 2023 and 2026: Price to Book soared 95.63% in 2023, then sank 448.97% in 2026.
• Over 5 years, Price to Book stood at 16.71 in 2022, then jumped by 95.63% to 0.73 in 2023, then jumped by 37.18% to 0.46 in 2024, then surged by 40.1% to 0.27 in 2025, then sank by 211.67% to 0.86 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 0.86, 0.27, and 0.21 for Q2 2026, Q4 2025, and Q3 2025 respectively.